This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Novo Nordisk Inc.
Novo Nordisk Inc., a leading global healthcare company, is headquartered in the United States and operates extensively across North America and beyond. Founded in 1923, Novo Nordisk has established itself as a pioneer in diabetes care, producing innovative insulin products and devices that cater to the needs of millions worldwide. The company is also a key player in the fields of obesity care, haemophilia, and growth hormone therapy, offering unique solutions that enhance patient outcomes. With a strong commitment to sustainability and research, Novo Nordisk has achieved significant milestones, including advancements in diabetes management technologies. Recognised for its market leadership, Novo Nordisk continues to set industry standards, driven by a mission to improve the lives of people with chronic conditions.
DitchCarbon Score
How does Novo Nordisk Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Novo Nordisk Inc.'s score of 73 is higher than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Novo Nordisk Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. However, the company is part of a broader commitment to sustainability and climate action, inheriting initiatives and targets from its parent company, Novo Nordisk A/S. As a current subsidiary, Novo Nordisk Inc. aligns with the climate strategies set forth by Novo Nordisk A/S, which includes participation in various initiatives such as the Science Based Targets initiative (SBTi), CDP, and RE100. These initiatives aim to drive significant reductions in greenhouse gas emissions across their operations. While specific reduction targets and achievements for Novo Nordisk Inc. are not detailed, the overarching commitments from Novo Nordisk A/S reflect a strong dedication to addressing climate change. The company is focused on reducing its carbon footprint and enhancing sustainability practices within the pharmaceutical industry. In summary, while specific emissions data for Novo Nordisk Inc. is not available, the company is actively engaged in climate commitments and initiatives inherited from its parent organisation, Novo Nordisk A/S, demonstrating a commitment to sustainability and responsible environmental stewardship.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 86,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 75,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Novo Nordisk Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
